137MO Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Longer-term follow-up from the Asian subgroup of the JAVELIN Bladder 100 trial

M. Eto, C.J. Desai,S.H. Park, N. Tsuchiya,P.J. Su,T.W. Chan,H.P. Gurney, S. Gao,J. Wang, R. Sandner,A. di Pietro,J-L. Lee

Annals of Oncology（2022）

Cited 0|Views1

No score

Abstract

In the JAVELIN Bladder 100 trial (NCT02603432), avelumab (anti–PD-L1) 1L maintenance + best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) vs BSC alone in patients with advanced UC that had not progressed with 1L platinum-based chemotherapy. Previously reported initial data from patients enrolled in Asia were consistent with data from the overall trial population. Here, we report longer-term efficacy and safety data from the Asian subgroup.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined